Stock Analiz

CRISPR Therapeutics AG (CRSP) stock forecast and price target

Price $42.24 · data as of November 13, 2026

12-month price target

Average target$85.42
Upside / downside+102.2%
Analysts19
ConsensusBuy
Low $44.00Average $85.42High $291.00

Gold marker: average target · white marker: today’s price ($42.24)

Analyst ratings

Strong buy 4Buy 9Hold 10Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-4.53+30.0%$35M
Next fiscal year
ends December 31, 2027
$-3.69+18.7%$134M
Next quarter
ends December 31, 2026
$-1.18+14.0%$13M
Quarter after
ends March 31, 2027
$-1.09+14.6%$11M

Consensus of the analysts covering CRISPR Therapeutics, updated daily. In the last 30 days 6 estimates were raised and 9 lowered.

Frequently asked questions

What is the CRISPR Therapeutics stock price target?

The average 12-month target from 19 analysts is $85.42, 102.2% above the current price of $42.24 Targets range from $44.00 to $291.00.

Is CRISPR Therapeutics a buy according to analysts?

The consensus rating is “Buy” (4 strong buy, 9 buy, 10 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is CRISPR Therapeutics expected to earn?

Analysts expect EPS of $-4.53 for the fiscal year ending December 31, 2026 and $-3.69 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.